Katherine Stueland Sells 3,639 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 3,639 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $33.33, for a total value of $121,287.87. Following the transaction, the chief executive officer now directly owns 95,457 shares in the company, valued at approximately $3,181,581.81. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Katherine Stueland also recently made the following trade(s):

• On Monday, July 29th, Katherine Stueland sold 2,154 shares of GeneDx stock. The stock was sold at an average price of $33.54, for a total value of $72,245.16.
• On Monday, June 17th, Katherine Stueland sold 7,683 shares of GeneDx stock. The shares were sold at an average price of $28.31, for a total transaction of $217,505.73.

GeneDx Stock Performance

Shares of GeneDx stock opened at $35.26 on Thursday. GeneDx Holdings Corp. has a 12 month low of $1.16 and a 12 month high of $37.45. The company has a current ratio of 2.38, a quick ratio of 2.22 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $921.06 million, a PE ratio of -6.81 and a beta of 2.29. The stock’s fifty day simple moving average is $32.49 and its 200 day simple moving average is $22.21.

GeneDx (NASDAQ:WGS) last released its quarterly earnings results on Tuesday, July 30th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.15. GeneDx had a negative return on equity of 22.71% and a negative net margin of 48.21%. On average, research analysts predict that GeneDx Holdings Corp. will post -0.75 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. BTIG Research increased their price objective on shares of GeneDx from $35.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, July 31st. Craig Hallum raised their price target on GeneDx from $43.00 to $46.00 and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Wells Fargo & Company began coverage on GeneDx in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $34.00 price objective for the company. The Goldman Sachs Group raised their target price on GeneDx from $28.00 to $32.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Finally, Jefferies Financial Group assumed coverage on GeneDx in a research note on Monday, June 3rd. They issued a “hold” rating and a $21.00 price target for the company. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, GeneDx presently has an average rating of “Moderate Buy” and a consensus target price of $38.00.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of WGS. Acadian Asset Management LLC bought a new stake in shares of GeneDx during the second quarter worth $34,000. nVerses Capital LLC acquired a new position in GeneDx in the 2nd quarter worth $50,000. Thompson Davis & CO. Inc. increased its holdings in GeneDx by 20.8% during the 1st quarter. Thompson Davis & CO. Inc. now owns 24,094 shares of the company’s stock worth $220,000 after purchasing an additional 4,150 shares in the last quarter. American Century Companies Inc. raised its stake in shares of GeneDx by 36.1% in the 2nd quarter. American Century Companies Inc. now owns 17,258 shares of the company’s stock valued at $451,000 after purchasing an additional 4,573 shares during the period. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of GeneDx in the second quarter valued at about $290,000. Institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.